This article identifies three more Israeli companies that are expected to receive FDA approval for treatments in 2023. They are Gamida Cell (Omidubicel / NiCord – bone marrow transplants); Protalix (PRX-102 – Fabry disease); and BioLineRX (BL-8040 / Motixafortide – multiple myeloma).
https://en.globes.co.il/en/article-four-israeli-cos-expect-fda-approvals-in-2023-1001434199